Issue Date: September 5, 2011
Merck Licenses Zymeworks Process
Merck & Co. will pay up to $187 million for access to bispecific antibody development technology from privately held Zymeworks. A bispecific antibody consists of two different heavy chains engineered into one molecule, enabling binding to two separate drug targets. Vancouver, British Columbia-based Zymeworks will receive an undisclosed up-front fee and research funding and could get regulatory milestones and royalties on any drugs that reach the market.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society